# Ipsen acquires Kartos Therapeutics for up to $1.75 billion to add Phase 3 myelofibrosis asset

> ma · REPORTED · 2026-06-29

French pharma company Ipsen agreed on June 29, 2026 to acquire Redwood City-based Kartos Therapeutics for $450 million upfront (up to $1.75 billion with milestones), gaining navtemadlin, an oral MDM2 inhibitor in a pivotal Phase 3 trial as an add-on to Jakafi in myelofibrosis patients with suboptimal responses. The deal is expected to close in Q3 2026 and contribute to Ipsen profits from 2029.

- Company: Ipsen / Kartos Therapeutics
- Sector: biotech
- Primary source: https://pharmaphorum.com/news/ipsen-charts-175bn-course-kartos-acquisition

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.